» Articles » PMID: 31225611

ESBLs and Resistance to Ceftazidime/avibactam and Ceftolozane/tazobactam Combinations in Escherichia Coli and Pseudomonas Aeruginosa

Overview
Date 2019 Jun 22
PMID 31225611
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To evaluate the efficacy of the recently launched β-lactam/β-lactamase inhibitor combinations ceftazidime/avibactam and ceftolozane/tazobactam against ESBL-producing Escherichia coli and Pseudomonas aeruginosa strains.

Methods: A series of ESBL-encoding genes (blaTEM, blaSHV, blaCTX-M, blaVEB, blaPER, blaGES and blaBEL) was cloned and expressed in E. coli or P. aeruginosa recipient strains. Cultures of E. coli TOP10 harbouring recombinant plasmids and therefore producing the different ESBLs tested were grown in order to perform measurements of catalytic activities, using benzylpenicillin, ceftazidime and ceftolozane as substrates. IC50s were additionally determined for clavulanic acid, tazobactam and avibactam.

Results: We showed here an overall better activity of ceftazidime/avibactam compared with ceftolozane/tazobactam toward ESBL-producing E. coli and P. aeruginosa. Several ESBLs of the GES, PER and BEL types conferred resistance to ceftolozane/tazobactam in E. coli and P. aeruginosa. For GES-6 and PER-1 producers, resistance to ceftolozane/tazobactam could be explained by a high hydrolysis of ceftolozane and a low activity of tazobactam as an inhibitor. On the other hand, PER-producing P. aeruginosa also exhibited resistance to ceftazidime/avibactam.

Conclusions: Altogether, the results show that the ESBL PER-1, which is widespread worldwide, may be a source of resistance to both ceftolozane/tazobactam and ceftazidime/avibactam. Excellent activity of ceftazidime/avibactam was highlighted for both ESBL-producing E. coli and ESBL-producing P. aeruginosa.

Citing Articles

Evaluation of Emerging Antimicrobials Resistance in Nosocomial Infections Caused by : The Comparison Results of Observed Cases and Compartmental Model.

Eshrati B, Karimzadeh-Soureshjani E, Nasehi M, Janani L, Baradaran H, Bitaraf S Interdiscip Perspect Infect Dis. 2025; 2025:3134775.

PMID: 39867137 PMC: 11756951. DOI: 10.1155/ipid/3134775.


Recent Advances in Antimicrobial Resistance: Insights from as a Model Organism.

Zhang Z, Wei M, Jia B, Yuan Y Microorganisms. 2025; 13(1).

PMID: 39858819 PMC: 11767524. DOI: 10.3390/microorganisms13010051.


Mechanisms leading to ceftazidime/avibactam resistance development during treatment of GES-5-producing infections.

Herrera C, Gomis-Font M, Lopez-Causape C, Diez-Aguilar M, Fraile-Ribot P, Cardenoso L Antimicrob Agents Chemother. 2024; 68(11):e0116424.

PMID: 39431817 PMC: 11539206. DOI: 10.1128/aac.01164-24.


Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms.

Falcone M, Galfo V, Tiseo G Curr Opin Infect Dis. 2024; 37(6):594-601.

PMID: 39149832 PMC: 11556876. DOI: 10.1097/QCO.0000000000001044.


Phenotypic and molecular characterization of multidrug-resistant Enterobacterales isolated from clinical samples in Palestine: a focus on extended-spectrum β-lactamase- and carbapenemase-producing isolates.

Ibaideya M, Taha A, Qadi M BMC Infect Dis. 2024; 24(1):812.

PMID: 39134953 PMC: 11318133. DOI: 10.1186/s12879-024-09726-x.